These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34647140)

  • 1. Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT.
    Benhalima K; van Nes F; Laenen A; Gillard P; Mathieu C
    Diabetologia; 2021 Dec; 64(12):2725-2730. PubMed ID: 34647140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
    Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
    Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of insulin pump therapy with predictive low glucose suspend feature in decreasing hypoglycemia in children with type 1 diabetes mellitus: A systematic review and meta-analysis.
    Alotaibi A; Al Khalifah R; McAssey K
    Pediatr Diabetes; 2020 Nov; 21(7):1256-1267. PubMed ID: 32738022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy.
    Danne T; Kordonouri O; Holder M; Haberland H; Golembowski S; Remus K; Bläsig S; Wadien T; Zierow S; Hartmann R; Thomas A
    Diabetes Technol Ther; 2011 Nov; 13(11):1129-34. PubMed ID: 21827318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes.
    Beato-Víbora PI; Quirós-López C; Lázaro-Martín L; Martín-Frías M; Barrio-Castellanos R; Gil-Poch E; Arroyo-Díez FJ; Giménez-Álvarez M
    Diabetes Technol Ther; 2018 Nov; 20(11):738-743. PubMed ID: 30256132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
    Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.
    Kim JY; Jin SM; Kang ES; Kwak SH; Yang Y; Yoo JH; Bae JH; Moon JS; Jung CH; Bae JC; Suh S; Moon SJ; Song SO; Chon S; Kim JH
    Diabetologia; 2024 Jul; 67(7):1235-1244. PubMed ID: 38634887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
    Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
    Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.
    Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Krӧger J; Weitgasser R; Bolinder J
    Diabetologia; 2018 Mar; 61(3):539-550. PubMed ID: 29273897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial.
    Brown SA; Beck RW; Raghinaru D; Buckingham BA; Laffel LM; Wadwa RP; Kudva YC; Levy CJ; Pinsker JE; Dassau E; Doyle FJ; Ambler-Osborn L; Anderson SM; Church MM; Ekhlaspour L; Forlenza GP; Levister C; Simha V; Breton MD; Kollman C; Lum JW; Kovatchev BP;
    Diabetes Care; 2020 Aug; 43(8):1822-1828. PubMed ID: 32471910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
    Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
    Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes.
    Seget S; Rusak E; Polanska J; Jarosz-Chobot P
    Diabetes Technol Ther; 2022 Nov; 24(11):824-831. PubMed ID: 35852811
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world outcomes of two different sensor-augmented insulin pumps with predictive low glucose suspend function in type 1 diabetes patients.
    Moreno-Fernandez J; Beato-Vibora P; Olvera P; Garcia-Seco JA; Gallego-Gamero F; Herrera MT; Muñoz-Rodriguez JR
    Diabetes Res Clin Pract; 2021 Nov; 181():109093. PubMed ID: 34653567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study.
    Sharifi A; De Bock MI; Jayawardene D; Loh MM; Horsburgh JC; Berthold CL; Paramalingam N; Bach LA; Colman PG; Davis EA; Grosman B; Hendrieckx C; Jenkins AJ; Kumareswaran K; Kurtz N; Kyoong A; MacIsaac RJ; Speight J; Trawley S; Ward GM; Roy A; Jones TW; O'Neal DN
    Diabetes Technol Ther; 2016 Dec; 18(12):772-783. PubMed ID: 27835037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of the low-glucose suspend feature of insulin pump during fasting during Ramadan in type 1 diabetes mellitus.
    Elbarbary NS
    Diabetes Metab Res Rev; 2016 Sep; 32(6):623-33. PubMed ID: 26789012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower versus standard sucrose dose for treating hypoglycemia in patients with type 1 diabetes mellitus in therapy with predictive low glucose suspend (PLGS) augmented insulin pumps: A randomized crossover trial in Santiago, Chile.
    Grassi B; Onetto MT; Zapata Y; Jofré P; Echeverría G
    Diabetes Metab Syndr; 2021; 15(3):695-701. PubMed ID: 33813244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France.
    Roze S; Smith-Palmer J; Valentine W; Payet V; de Portu S; Papo N; Cucherat M; Hanaire H
    Diabetes Technol Ther; 2016 Feb; 18(2):75-84. PubMed ID: 26646072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
    Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
    N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.